Related Experiment Video
Updated: Sep 22, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Early detection of lung cancer via biointerference-free, target microRNA-triggered core-satellite nanocomposites
Cairou Chen1, Jing Wang2, Dechan Lu1,2
1College of Chemistry and Materials Science, Fujian Provincial Key Laboratory of advanced Oriented Chemical Engineer, Fujian Key Laboratory of Polymer Materials, Fujian Normal University, Fuzhou, Fujian, 350007, China. youruiyun@fjnu.edu.cn.
Abstract:
MicroRNAs (miRNAs) are emerging as essential liquid biopsy markers for early cancer detection. Currently, the clinical applications of miRNAs are lagging behind due to their high sequence similarity and rarity. Herein, we propose biointerference-free, target-triggered core-satellite nanocomposites for ultrasensitive surface-enhanced Raman spectroscopy (SERS) detection of lung cancer-related miRNA-21. Through the hybridization-based recognition effect, we observe an enormous SERS signal enhancement caused by miRNA-21-triggered assembly of core-satellite nanocomposites. This enables the sensitive detection of miRNA-21 down to the 0.1 fM level in a linear range of 10 fM to 1 nM. The use of a biointerference-free reporter further allows quantitative and direct detection of miRNA-21 from complex plasma samples, without RNA pre-extraction. As a proof of principle, we measure the level of plasma miRNA-21 in 20 lung cancer patients and 10 healthy participants. Significantly higher levels of miRNA-21 are determined in lung cancer patients than in healthy participants, with clear lower expression in stage I (n = 10) than in stage III-IV (n = 10) lung cancer patients. We, therefore, believe that this proposed strategy will have high clinical potential for sensitive quantification of miRNA markers in liquid biopsy samples and act as a complementary method for the early detection of lung cancer.

